BACKGROUND: The thrombin inhibitor dabigatranetexilat is used for prophylaxis of venous thromboembolism after total hip or knee replacement surgery (THR/TKR). Patients can take it orally in hospitals. METHOD: In a managerial pharmacoeconomic analysis of six German acute-care hospitals and six German rehabilitation hospitals, the use of dabigatranetexilat was compared with the use of low-molecular-weight heparins. RESULTS: The analysis showed that the new drug led to an economic advantage for an acute-care hospital of 2.43 euro per patient per day. In a rehabilitation hospital, the use of dabigatranetexilat led to an economic advantage of 1.40 euro per patient per day. CONCLUSION: These results have direct implications for drug decisions in hospitals. To demonstrate that fact, the price difference between dabigatranetexilat and low-molecular-weight heparins was derived to lead exactly to their"economic neutrality" from the hospital's point of view.
BACKGROUND: The thrombin inhibitor dabigatranetexilat is used for prophylaxis of venous thromboembolism after total hip or knee replacement surgery (THR/TKR). Patients can take it orally in hospitals. METHOD: In a managerial pharmacoeconomic analysis of six German acute-care hospitals and six German rehabilitation hospitals, the use of dabigatranetexilat was compared with the use of low-molecular-weight heparins. RESULTS: The analysis showed that the new drug led to an economic advantage for an acute-care hospital of 2.43 euro per patient per day. In a rehabilitation hospital, the use of dabigatranetexilat led to an economic advantage of 1.40 euro per patient per day. CONCLUSION: These results have direct implications for drug decisions in hospitals. To demonstrate that fact, the price difference between dabigatranetexilat and low-molecular-weight heparins was derived to lead exactly to their"economic neutrality" from the hospital's point of view.
Authors: H Van Aken; C Bode; H Darius; C Diehm; A Encke; D C Gulba; S Haas; W Hacke; W Puhl; M Quante; H Riess; R Scharf; S Schellong; T Schrör; K L Schulte; U Tebbe Journal: Clin Appl Thromb Hemost Date: 2001-07 Impact factor: 2.389
Authors: B I Eriksson; O E Dahl; H R Büller; R Hettiarachchi; N Rosencher; M-L Bravo; L Ahnfelt; F Piovella; J Stangier; P Kälebo; P Reilly Journal: J Thromb Haemost Date: 2005-01 Impact factor: 5.824
Authors: William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray Journal: Chest Date: 2004-09 Impact factor: 9.410
Authors: Bengt I Eriksson; Ola E Dahl; Nadia Rosencher; Andreas A Kurth; C Niek van Dijk; Simon P Frostick; Martin H Prins; Rohan Hettiarachchi; Stefan Hantel; Janet Schnee; Harry R Büller Journal: Lancet Date: 2007-09-15 Impact factor: 79.321
Authors: S Müller; T Wilke; M Pfannkuche; I Meber; A Kurth; H Merk; F Steinfeldt; D Ganzer; C Perka Journal: Orthopade Date: 2011-07 Impact factor: 1.087